Business
Beckman Coulter Diagnostics Launches Industry First Fully Automated, High Throughput BD-Tau Research Use Only Immunoassay Test, Advancing Neurodegenerative Clinical Research
Beckman Coulter Diagnostics, a Danaher company and a leader in global clinical diagnostics innovation, today launched the industry's first fully automated Brain-derived Tau (BD-Tau) research use only (RUO) immunoassay test. Access BD-Tau, along with Beckman Coulter Diagnostics' expanding portfolio of neurodegenerative disease RUO assays, is available for use on the groundbreaking DxI 9000 Immunoassay Analyzer and Access 2 Analyzer. This portfolio of assays enables precision medicine research on
About this update from Danaher Corporation
[{"type":"text","content":"Beckman Coulter Also Announces Development of Aß-42 Research Use Only Immunoassay Test","length":86,"tagName":"p","attribs":{}},{"type":"text","content":"BREA, Calif., Sept. 10, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a Danaher company and a leader in global clinical diagnostics innovation, today launched the industry's first fully automated Brain-derived Tau (BD-Tau) research use only (RUO) immunoassay test. Access BD-Tau, along with Beckman Coulter Diagnostics' expanding portfolio of neurodegenerative disease RUO assays, is available for use on the groundbreaking DxI 9000 Immunoassay Analyzer and Access 2 Analyzer. This portfolio of assays enables precision medicine research on clinical-grade platforms for a variety of neurodegenerative diseases and includes p‑Tau217, NfL, GFAP and APOE ε4.","length":672,"tagName":"p"},{"type":"image","alt":"The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Beckman Coulter’s Access p‑Tau217/β-Amyloid 1-42 plasma ratio Test.","displaySize":"","headline":null,"caption":"The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Beckman Coulter’s Access p‑Tau217/β-Amyloid 1-42 plasma ratio Test.","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/91fc0df35b518a8b7f4a90ba0b6fc8cf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2DbBzJ8fGNMXH8Ueg6_Vww--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/91fc0df35b518a8b7f4a90ba0b6fc8cf","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/2769306/Beckman_Coulter_Diagnostics_p_Tau_plasma_ratio_Test.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"BD-Tau, an isoform of brain-derived tau, is emerging as a highly promising blood-based biomarker for neurodegenerative research. Studies across several cohorts reveal a strong relationship between plasma BD-Tau and cerebrospinal fluid (CSF) total tau (t-tau), with this association becoming even more pronounced when both amyloid-β (Aβ) and tau tangle (N) abnormalities are present. Unlike total tau (t-tau) and phosphorylated tau (p-tau), BD-Tau offers enhanced specificity; by detecting the short form of brain-derived tau dir...